Table 3 Baseline characteristics of completers and non-completers of the 3-dose regimen of the quadrivalent HPV vaccine
Characteristic * | Completers (N = 1215) | Non-Completers (N = 210) | Adjusted OR †(95% CI) |
|---|---|---|---|
Socio-demographics | |||
Age (mean ± SD) | 13.2 ± 0.3 | 13.2 ± 0.3 | 1.02 (0.60-1.75) |
Neighbourhood income quintile | |||
   1 (lowest) | 16.9 | 31.0 | 0.45 (0.28-0.72)††|
   2 | 17.5 | 17.6 | 0.80 (0.48-1.33) |
   3 (reference) | 21.5 | 17.1 | 1.00 (reference) |
   4 | 21.0 | 16.7 | 0.98 (0.59-1.62) |
   5 (highest) | 22.7 | 16.2 | 1.15 (0.68-1.92) |
   Missing‡ | 0.4 | 1.4 | 0.56 (0.12-2.66) |
Place of residence | |||
   Urban (reference) | 77.7 | 82.4 | 1.00 |
   Rural | 21.9 | 16.2 | 1.76 (1.14-2.74)††|
   Missing‡ | 0.4 | 1.4 | 0.56 (0.12-2.66) |
Vaccination History | |||
MMR | 96.8 | 92.4 | 1.61 (0.81-3.19) |
Meningococcal C | 90.0 | 79.5 | 1.39 (0.83-2.35) |
Hepatitis B | 92.3 | 81.9 | 1.67 (0.95-2.92) |
All three vaccines§ | 85.1 | 72.4 | 1.85 (1.29-2.65)††|
Health Services Utilisation | |||
Hospitalizations‖ | |||
   None (reference) | 18.8 | 23.8 | 1.00 |
   1 | 63.1 | 54.8 | 1.23 (0.80-1.91) |
   2 | 12.9 | 13.8 | 1.08 (0.59-1.98) |
   ≥ 3 | 5.2 | 7.6 | 1.04 (0.45-2.37) |
Emergency Department visits‖ | |||
   None (reference) | 26.3 | 23.3 | 1.00 |
   1 | 21.5 | 21.9 | 0.85 (0.53-1.35) |
   2-7 | 43.3 | 43.8 | 0.88 (0.58-1.35) |
   ≥ 8 | 8.9 | 11.0 | 0.73 (0.38-1.40) |
Outpatient visits‖ | |||
   0-13 (reference) | 7.6 | 13.8 | 1.00 |
   14-45 | 41.2 | 38.1 | 1.42 (0.79-2.54) |
   46-92 | 40.7 | 35.7 | 1.55 (0.83-2.89) |
   ≥ 93 | 10.5 | 12.4 | 1.43 (0.67-3.05) |
Medical History | |||
Previous diagnosis | |||
   Infectious and parasitic diseases | 14.5 | 19.1 | 0.83 (0.48-1.42) |
   Intestinal infections | 3.2 | 6.7 | 0.64 (0.28-1.45) |
   Chickenpox | 1.5 | 2.4 | 0.80 (0.25-2.59) |
   Cancer | 0.9 | 1.0 | 0.80 (0.16-3.98) |
   Metabolic disorders | 3.0 | 3.3 | 1.33 (0.50-3.56) |
   Disorders of the immune system | 0.1 | 0.0 | - |
   Diseases of the blood | 1.6 | 0.5 | 4.60 (0.56-37.84) |
   Mental disorders | 0.5 | 0.5 | 0.84 (0.09-8.36) |
   Epilepsy, seizures, and convulsions | 3.1 | 3.8 | 0.89 (0.38-2.07) |
   Gastroenteritis | 5.3 | 7.1 | 0.70 (0.36-1.37) |
   Nephritis | 3.5 | 5.7 | 0.62 (0.29-1.30) |
   Congenital anomalies | 7.0 | 7.1 | 0.96 (0.52-1.78) |
   Syncope | 1.2 | 1.0 | 1.62 (0.34-7.77) |
   Other serious illness | 2.1 | 1.4 | 1.66 (0.45-6.14) |
Immune-mediated events | |||
   Allergic rhinitis | 0.3 | 0.0 | - |
   Asthma | 5.4 | 6.7 | 0.89 (0.46-1.75) |
   Dermatitis | 4.4 | 3.3 | 1.72 (0.72-4.14) |
Autoimmune diseases | |||
   Diabetes mellitus | 1.3 | 1.4 | 0.77 (0.21-2.83) |
   Multiple sclerosis | 0.0 | 0.0 | - |
   Bell's palsy | 0.3 | 0.0 | - |
   Guillain-Barré Syndrome | 0.0 | 0.0 | - |
   Juvenile Arthritis | 1.9 | 3.8 | 0.58 (0.24-1.41) |
   Systemic Lupus Erythematosus | 0.0 | 0.0 | - |
Risk factors for autoimmune diseases | |||
   Cytomegalovirus¶ | 0.0 | 0.0 | - |
   Epstein-Barr virus¶ | 0.3 | 0.0 | - |
   Campylobacter | 0.0 | 0.0 | - |
   Influenza | 15.9 | 13.3 | 1.26 (0.80-1.97) |
   Mycoplasma pneumoniae | 0.1 | 0.0 | - |